Comments
Fresenius Kabi (Singapore) Pte Ltd is planning to delist its Indian arm Fresenius Kabi Oncology (FKOL) by buying out 19 per cent stake held by the public.
The company has received a letter from Fresenius Kabi (Singapore) Pte Ltd (FKSL) about its intention to make a voluntary delisting offer to the public shareholders of FKOL, Fresenius Kabi Oncology said in a filing to the BSE.
Fresenius Kabi (Singapore) Pte Ltd holds 81 per cent of the total stake in Fresenius Kabi Oncology.
FKSL intends to pay an indicative price of up to Rs 130 per share to acquire the scrips offered to it in the delisting offer, it added.
This is being done due to a change in the India strategy of the promoter entity, FKOL said.
“Delisting of FKOL will be a step towards FKSL obtaining full ownership of FKOL and enable integration of FKOL in Fresenius global operations,” it added.
Shares of Fresenius Kabi Oncology today closed at Rs 134.20 on the BSE, up 5.63 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.